Jaka jest cena za Psyence Biomedical Ltd. (PBM)

Cena za Psyence Biomedical Ltd. (PBM) wynosi $3.20

Jaka jest kapitalizacja rynkowa dla Psyence Biomedical Ltd. (PBM)

Kapitalizacja rynkowa dla Psyence Biomedical Ltd. (PBM) wynosi $60.86K

Psyence Biomedical Ltd. (PBM) Cena i Kapitalizacja Rynkowa

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Cena za PBM	Aktywa B	Kapitalizacja rynkowa B	Wyniki
$286,436,535 $60.86K	NVDA	$5.448T	+8,951,141,613.39%
$234,824,702 $60.86K	AAPL	$4.466T	+7,338,271,850.52%
$219,555,251 $60.86K	GOOG	$4.176T	+6,861,101,488.68%
$194,872,372 $60.86K	MSFT	$3.706T	+6,089,761,526.12%
$151,976,064 $60.86K	AMZN	$2.890T	+4,749,251,914.43%

Cena za PBM

Aktywa B

Kapitalizacja rynkowa B

Wyniki

$286,436,535 $60.86K